We address today’s need for a favorable outcome of cancer
treatment with low toxicity and patient friendly administration.
Learn More
BP-C1 Oncology BP-C1 is a unique product that clinically has proven to have both
strong palliation properties as well as tumor control properties.
Read More
BP-C2 Radiation Defence BP-C2 incorporates immunomodulating and chelating ligand
and a molybdenum, needed for detoxification.
Read More

Meabco A/S focuses on 3 therapeutic cancer challenges

Meabco A/S is a privately held oncology biotechnology company established in 2001 developing breakthrough cancer therapy products to significantly improve life with cancer.

Pancreatic cancer

  • Affects 350.000 new patients globally every year.
  • 4th leading killer in cancer with 3% survival rate after 5 years.
  • The vast majority of patients have chemotherapy during the course of their disease but the combination of progressive disease and toxic chemotherapy results in a very poor quality of life.

Metastatic Breast Cancer

  • Breast cancer globally affects 1.7 million patients WW every year of which metastatic disease is present at diagnosis in 20-33%.
  • The 5-year survival rate is 22% in metastatic diseases.
  • Patients undergoing chemotherapy, anti-hormonal and targeted therapy may have troublesome toxicity caused by the treatment.

Palliative treatment of radiation and chemotherapy

  • Seven million cancer patients are treated with radiation WW.
  • Nearly all of the 14 million cancer patients WW are treated with chemotherapy.

Treatment of incurable pancreatic cancer

Clinical development in pancreatic cancer is well underway with favorable results.

Read more

Treatment of metastatic breast cancer

Randomized double-blinded placebo-controlled studies in metastatic breast cancer patients have been completed with favorable results.

Read more

Palliation of Prostate cancer

Trial protocols in palliation of prostate cancer are being initiated.

Read more